Massachusetts Institute of Technology

National University of Singapore

Harvard College

Children's Medical Center Corporation

California Institute of Technology

The General Hospital Corporation

The State University of New York

Boston University

Tufts University

Whitehead Institute for Biomedical Research

President and Fellows of Havard College

Appia, LLC

Gregory N Stephanopoulos

Parayil K Ajikumar

Heng Phon Too

Rahul Singhvi

George M Whitesides

Donald Elliot Ingber

Amit Kumar

Gabriel P Lopez

Hal S Alper

Daniel I C Wang

Mitchell Tai

Maria Flytzani-Stephanopoulos

Daniel I Wang

Christopher R Loose

Mark A Applegate

Yong-Su Jin

Jose Luis Avalos

Kyle Jensen

Syed Hussain Imam Abidi

Brian Pereira

Sagar Chakraborty

Christine Santos

Seujeung Park

James Joseph Collins

Julia A Kornfield

Timothy Kuan-Ta Lu

Michael R Hoffmann

Gerald R Fink

Christine Nicole S Santos

Gerald E Voecks

Kristala Lanett Jones Prather

Curt R Fischer

Marjan De Mey

Deepak Dugar

Branko Zugic

Othon Iliopoulos

Ruiyang Zou

Georg Bohm

Mattheos Koffas

Zheng-Jun Li

Elke Nevoigt

Tina Lutke-Eversloh

Kelly Thayer

Robert G Arnold

Nian Liu

Junyoung Park

Max J Kennedy

Effendi Leonard

Daniel Klein-Marcuschamer

Too Heng Phon

Brian Ricks

Paulo Alexandre Da Costa Gameiro Guerreiro

Joanne K Kelleher

Christian M Metallo

Kristen Jean Fortnam

Devin Hedley Currie

Christopher Jongsoo Yoon

Tanguy My Chau

Valerie Ward

Alkiviadis Orfefs Chatzivasileiou

Steven McBride Edgar

Peng Xu

Kangjian Qiao

Some aspects of this invention provide methods and bioreactors for converting a carbon source into a lipid. In some embodiments, lipid production is carried out in an aerobic fermentor and carbon dioxide generated during lipid production is converted into a carbon substrate by COfixation in an anaerobic fermentor. In some embodiments, the carbon substrate generated by CO2 fixation is used as the carbon source for lipid production, thus achieving total carbon utilization in lipid production.

Bioprocess and microbe engineering for total carbon utilization in biofuel production

The disclosure provides methods using mixed substrate cofeeding for bioproduct synthesis, which enables faster, more efficient, and higher yield carbon conversion in various organisms.

Controlling metabolism by substrate cofeeding

The invention relates to the production of one or more terpenoids through microbial engineering, and relates to the manufacture of products comprising terpenoids.

Microbial engineering for the production of chemical and pharmaceutical products from the isoprenoid pathway

The invention provides, inter alia, a nucleic acid (e.g. expression vector) that comprises at least a first coding sequence and a second coding sequence. Each conding sequence is under the control of an inducible promoter of defined strength. Different promoters can have different strengths. Each promoter is responsive to the same inducer. The invention also provides: methods of expressing coding regions, methods of making a product of a multi-enzyme pathway, and methods of optimizing the yield of a product of a multi-enzyme metabolic pathway using the nucleic acids provided by the invention. Also disclosed is a method of non-enzymatic gene cloning useful for practicing the invention.

Univariant extrinsic initiator control system for microbes and an in vitro assembly of large recombinant DNA molecules from multiple components

Some aspects provide engineered microbes for oil production. Methods for microbe engineering and for use of engineered microbes are also provided herein. Such engineered microbes exhibit greatly enhanced conversion yields and TAG synthesis and storage properties.

Isolated oleaginous yeast

Metabolic flux biosensors are provided herein, as are related compositions and methods useful for, inter alia, identifying factors which increase the production of metabolites and/or end products of metabolic pathways, and for the production of inter alia, metabolites and/or end products of metabolic pathways.

Metabolic flux biosensor

Disclosed herein are engineered cells and cell-free systems, compositions, and methods for conversion of isopentenols to isoprenoid precursors.

Microbial engineering for the production of isoprenoids

The present invention is generally related to engineered bacteriophages expressing antimicrobial peptides or lytic enzymes or fragments thereof for targeting a broad spectrum of bacterial hosts, and for the long-term suppression of bacterial phage resistance for reducing bacterial infections. In some embodiments, bacteriophages express antimicrobial peptides or antimicrobial polypeptides (e.g. phage lytic enzymes) which are secreted from the host bacteria, or alternatively released upon lysis of the bacterial host cell. Aspects of the present invention also relate to the use of the engineered bacteriophages for the reduction of bacterial infections, both in a subject or for bioremediation purposes, in clinical settings and wound healing.

Bacteriophages expressing antimicrobial peptides and uses thereof

Some aspects provide engineered microbes for glycolate production. Methods for microbe engineering and culturing are also provided herein. Such engineered microbes exhibit greatly enhanced capabilities for glycolate production.

Microbial production of renewable glycolate

The invention relates to recombinant expression of a taxadiene synthase enzyme and a geranylgeranyl diphosphate synthase (GGPPS) enzyme in cells and the production of terpenoids.

Aspects of the invention relate to methods for producing lactic acid from organic waste, comprising contacting organic waste with a microbial community to form a fermentation mixture, and fermenting the fermentation mixture under controlled pH and temperature conditions for a time sufficient to produce lactic acid.

Method for producing lactic acid from organic waste

A novel pathway in cancer cell metabolism is identified. Targeting of any gene, protein, or enzyme that modulates activity or flux through this pathway, including, but not limited to IDH1, isocitrate dehydrogenase 2 (IDH2), aconitase 1 (ACO1), aconitase 2 (ACO2), glutaminase (GLS), glutamate dehydrogenase (GDH) and transaminase, provides effective means of inhibiting tumor growth.

Metabolic gene, enzyme, and flux targets for cancer therapy

Growing community of inventors

Winchester, MA, United States of America

Gregory N Stephanopoulos